Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 19, 2019 - Issue 8: Special Focussed Issue on Migraine
Submit an article Journal homepage
296
Views
12
CrossRef citations to date
0
Altmetric
Drug Profile

Fremanezumab as a preventive treatment for episodic and chronic migraine

Marcelo E. BigalPurdue Pharma, Stamford, CT, USACorrespondence[email protected]
View further author information
,
Sarah WalterAntiva Biosciences, San Francisco, CA, USAView further author information
&
Alan M. RapoportDepartment of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USAView further author information
Pages 719-728 | Received 30 Jan 2019, Accepted 30 Apr 2019, Published online: 22 May 2019

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Abouch Krymchantowski, Raimundo Pereira Silva-Néto, Carla Jevoux & Ana Gabriela Krymchantowski. (2022) Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies. Postgraduate Medicine 134:6, pages 598-602.
Read now
Enrico Bentivegna, Michelangelo Luciani, Valeria Ferrari, Silvia Galastri, Francesco Baldari, Francesco Scarso, Piera A. Lamberti & Paolo Martelletti. (2022) Recently approved and emerging drug options for migraine prophylaxis. Expert Opinion on Pharmacotherapy 23:11, pages 1325-1335.
Read now
Abouch V. Krymchantowski, Carla C. Jevoux, Ana G. Krymchantowski, Rodrigo Salvador Vivas & Raimundo Silva-Néto. (2020) Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments. Expert Review of Neurotherapeutics 20:6, pages 591-600.
Read now

Articles from other publishers (9)

Valeria Caponnetto, Antonio Russo, Marcello Silvestro, Alessandro Tessitore, Roberto De Icco, Gloria Vaghi, Grazia Sances, Cristina Tassorelli, Carlo Baraldi, Flavia Lo Castro, Simona Guerzoni, Maria Pia Prudenzano, Adriana Fallacara, Martino Gentile, Raffaele Ornello, Agnese Onofri, Andrea Burgalassi, Alberto Chiarugi, Francesco De Cesaris, Antonio Granato, Alfonsina Casalena, Marina De Tommaso, Edoardo Mampreso, Paola Merlo, Gianluca Coppola, Stefania Battistini, Valentina Rebecchi, Innocenzo Rainero, Federica Nicoletta Sepe, Giorgio Dalla Volta, Simona Sacco, Pierangelo Geppetti, Luigi Francesco Iannone, Marta Allena, Daria Brovia, Giorgio Liaci, Giorgio Tabasso, Giulia Vigani, Gabriele Garascia, Paolo Manganotti, Anna La Porta, Natascia Beretta, Stefano Tronci & Claudio Baiata. (2023) Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study. CNS Drugs 37:12, pages 1069-1080.
Crossref
Enrico Bentivegna, Dilara Onan & Paolo Martelletti. (2023) Unmet Needs in Preventive Treatment of Migraine. Neurology and Therapy 12:2, pages 337-342.
Crossref
Michel D. Ferrari, Karin W. M. Zuurbier, Steve Barash, Xiaoping Ning & Joshua M. Cohen. (2022) Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache: The Journal of Head and Face Pain 62:4, pages 530-533.
Crossref
Bixi Gao, Qiran Lu, Rong Wan, Zilan Wang, Yanbo Yang, Zhouqing Chen & Zhong Wang. (2020) Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials. Naunyn-Schmiedeberg's Archives of Pharmacology 394:4, pages 819-828.
Crossref
Laurent F Martin, Amol M Patwardhan, Sejal V Jain, Michelle M Salloum, Julia Freeman, Rajesh Khanna, Pooja Gannala, Vasudha Goel, Felesia N Jones-MacFarland, William DS Killgore, Frank Porreca & Mohab M Ibrahim. (2020) Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. Cephalalgia 41:2, pages 135-147.
Crossref
Mushref Bakri Assas. (2021) Anti-migraine agents from an immunological point of view. Journal of Translational Medicine 19:1.
Crossref
Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Anh L. Ngo, Alan D. Kaye, Rachel J. Kaye, Elyse M. Cornett & Omar Viswanath. (2020) An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain and Therapy 9:1, pages 195-215.
Crossref
Bixi Gao, Nan Sun, Yanbo Yang, Yue Sun, Mingjia Chen, Zhouqing Chen & Zhong Wang. (2020) Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials. Frontiers in Neurology 11.
Crossref
Cinzia Cavestro, Marcella Ferrero, Silvia Mandrino, Marco Di Tavi & Eugenia Rota. (2019) Novelty in Inflammation and Immunomodulation in Migraine. Current Pharmaceutical Design 25:27, pages 2919-2936.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.